Articles Related to myeloproliferative neoplasm

Patients with Philadelphia-negative myeloproliferative neoplasms (PN-MPN) are at a higher risk for venous thrombosis. Thromboelastometry may prove efficient to evaluate the patient’s thrombotic risk. In this study, based on data from 114 patients with PN-MPN from a single center in Greece, hemostatic profile was assessed with routine coagulation tests, Rotational Thromboelastometry (ROTEM® ), and Platelet Function Analyzer (PFA)-100 and correlated with clinical, laboratory, treatment characteristics, gene mutations and polymorphisms of poly (ADP-ribose) polymerase-1 (PARP-1)

View complete article: PDF  |  Full-text

We report here for the first time the efficacy of pegylated interferon α2a (Peg-Ifn) as a therapy for patients with myelofibrosis and high blast counts. We treated four patients who were in an accelerated phase of myeloproliferative neoplasms or acute panmyelosis with myelofibrosis using only this drug.

View complete article: PDF  |  Full-text

The WHO defined JAK2V617F mutated myeloproliferative neoplasms (MPN) consist of normocellular essential thrombocythemia (ET), ET with features of early PV (prodromal PV), ET with hypercelular megakaryocytic granulocytic myeloproliferation (ET.MGM), and various stages of polycythemia vera (PV) when the WHO and European Clinical and Pathological (WHO-ECMP) criteria are applied.

View complete article: PDF  |  Full-text

Multiple myeloma is a neoplastic disease characterized by neoplastic proliferation of plasma cells and monoclonal protein expression and related tissue damage.In the presence of overt clinical signs, the disease can easily be diagnosed, however in order to diagnose atypical cases, further investigation is needed with high clinical suspicion.

View complete article: PDF  |  Full-text